Cannabis Report
Lithium
Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Foxwoods Man, drkazmd65
Search This Board: 
Last Post: 8/17/2018 9:14:51 AM - Followers: 209 - Board type: Free - Posts Today: 11

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/

https://www.youtube.com/watch?v=auAihG3rtC4

Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
    The scientific, clinical, and commercial development of the medicine and
    CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
     
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  

    Teva Pharmaceuticals Industries Ltd.
     
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  

     
    Orient Europharma Co. Ltd.
     
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  

     
    IDC-GP Pharm LLC 
     
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  

     

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.




http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

 

Cannabis Report
Lithium
CVM
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM News: CEL-SCI Announces That the NYSE American Approves Plan 08:00 AM
CVM News: Statement of Changes in Beneficial Ownership (4) 08/15/2018 02:23:50 PM
CVM News: Statement of Changes in Beneficial Ownership (4) 08/15/2018 02:20:55 PM
CVM News: Statement of Changes in Beneficial Ownership (4) 08/15/2018 02:18:30 PM
CVM News: CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head & Neck Cancer St... 08/15/2018 08:30:00 AM
News News Alert: CEL-SCI Announces That the NYSE American Approves Plan 08/17/2018 08:00:00 AM
PlusOneCoin Top Posts
#15795   Doctors & Standard of care yankeesnyc27 08/17/18 01:40:57 AM
PostSubject
#12411  Sticky Note Vienna, VA, January 3, 2018 -- CEL-SCI Foxwoods Man 01/03/18 08:19:00 AM
#7838  Sticky Note $CVM recent news/filings mick 01/18/16 02:09:58 PM
#5747  Sticky Note They keep coming!! Foxwoods Man 04/02/14 08:51:19 AM
#15805   CEL-SCI Announces That the NYSE American Approves Plan Source: trickledownfacists 08/17/18 09:14:51 AM
#15804   R/S does not help with compliance. trickledownfacists 08/17/18 09:13:17 AM
#15803   Yes they were done dosing trickledownfacists 08/17/18 09:12:30 AM
#15802   Well I sure hope that the new "Plan" PARker1703 08/17/18 08:37:24 AM
#15801   What were the details of the point in lightrock 08/17/18 08:33:44 AM
#15800   ARGS Asked not to proceed. Proceeded, and failed trickledownfacists 08/17/18 07:57:03 AM
#15799   Correct. SOC determines the treatment used. trickledownfacists 08/17/18 07:56:20 AM
#15798   Hmmm.....that is an enlightening reply. Yankee. Thank you. zeezeeman 08/17/18 03:30:56 AM
#15797   My ,my, my ""With Cancer TREATMENTS" popping up Turney 08/17/18 02:43:01 AM
#15796   They have asked others not to proceed 2 lightrock 08/17/18 01:40:58 AM
#15795   Doctors & Standard of care yankeesnyc27 08/17/18 01:40:57 AM
#15794   "Why are YOU DEFENDING posters that seem intent trickledownfacists 08/16/18 11:57:35 PM
#15793   They have asked quite a few other to trickledownfacists 08/16/18 11:52:29 PM
#15792   Weak attempt. Please reread your last 5 CVM posts. Trustbaby 08/16/18 08:41:30 PM
#15791   With cancer treatment popping up all over, what's zeezeeman 08/16/18 08:20:13 PM
#15790   I like it... lightrock 08/16/18 07:10:31 PM
#15789   I am getting numbers closer to yours, and Spideyboy 08/16/18 06:58:16 PM
#15788   I'm taking SOC only as placebo. Given that Spideyboy 08/16/18 06:49:49 PM
#15787   42% way over at the right comes from lightrock 08/16/18 06:44:24 PM
#15786   No 3/7 is MK + CIZ ( implied +SOC ) lightrock 08/16/18 06:41:55 PM
#15785   One query at this time. Spideyboy 08/16/18 06:39:27 PM
#15784   Much appreciated, I will review this carefully and Spideyboy 08/16/18 06:31:54 PM
#15783   This is mine lightrock 08/16/18 06:29:21 PM
#15782   Fact is that given the 5 year survival lightrock 08/16/18 06:22:39 PM
#15781   OK, so I ran an analysis and made Spideyboy 08/16/18 06:16:16 PM
#15780   Contact CEL-SCI and ask them what arms compare lightrock 08/16/18 06:00:45 PM
#15779   If you see the clinical trial site: Spideyboy 08/16/18 05:39:23 PM
#15778   Contact Investor Relations (IR) of a publicly traded lightrock 08/16/18 05:14:15 PM
#15777   2. SOC + Multikine alone ( NEVER HAPPENED ) yankeesnyc27 08/16/18 05:13:13 PM
#15776   Yes I still disagree but that is a lightrock 08/16/18 05:04:48 PM
#15775   Ok, yes there are 3 arms, but realistically Spideyboy 08/16/18 05:00:03 PM
#15774   quoting IR is like quoting S/A. yankeesnyc27 08/16/18 04:57:13 PM
#15773   All I'm doing is trying to help yankeesnyc27 08/16/18 04:54:18 PM
#15772   math is math lightrock 08/16/18 04:51:52 PM
#15771   YOU CAN TORTURE A STATISTIC & MAKE IT yankeesnyc27 08/16/18 04:50:02 PM
#15770   Your writing doesn't really make any sense. Believe staticmirror79 08/16/18 04:48:28 PM
#15769   Also as you did not take time to lightrock 08/16/18 04:35:03 PM
#15768   No Check your math, there are three arms lightrock 08/16/18 04:29:23 PM
#15767   "The purpose of this study is to determine yankeesnyc27 08/16/18 04:24:49 PM
#15766   Here are two articles citing my 3 arm staticmirror79 08/16/18 04:06:24 PM
#15765   What a M/B poster is talking about is yankeesnyc27 08/16/18 03:53:59 PM
#15764   I just don't think it's commonly known is staticmirror79 08/16/18 03:34:56 PM
#15763   3? why did Kersten just say 2???? yankeesnyc27 08/16/18 03:19:47 PM
#15762   I know lightrock will say this better than staticmirror79 08/16/18 03:16:12 PM
#15761   ****R/S & IDMC totally unrelated.**** yankeesnyc27 08/16/18 02:53:52 PM
#15760   Incorrect, As we are dividing the total population of Spideyboy 08/16/18 02:40:13 PM
#15759   With all due respect, you had the same Trustbaby 08/16/18 02:29:44 PM
#15758   The IDMC is a group of opinionated MESSAGE yankeesnyc27 08/16/18 02:25:56 PM
#15757   SeaAlice,Trustbaby, and Spidey lightrock 08/16/18 02:15:20 PM
#15756   As mentioned by Sea Alice and trust baby, Spideyboy 08/16/18 02:13:14 PM
PostSubject